TracyAnn Perry

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Behavioural, histological and immunocytochemical consequences following 192 IgG-saporin immunolesions of the basal forebrain cholinergic system
    T Perry
    Department of Psychology, Institute of Psychiatry, King s College London, London, United Kingdom
    Brain Res Bull 54:29-48. 2001
  2. ncbi request reprint A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells
    TracyAnn Perry
    Section of Drug, Design, and Development, Laboratory of Neuroscience, Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Pharmacol Exp Ther 300:958-66. 2002
  3. ncbi request reprint Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4
    TracyAnn Perry
    Section of Drug Design and Development, Laboratory of Neuroscience, Gerontology Research Center, National Institute on Aging NIH, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 302:881-8. 2002
  4. ncbi request reprint Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron
    TracyAnn Perry
    Section of Drug Design and Development, Laboratory of Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Neurosci Res 72:603-12. 2003
  5. ncbi request reprint The glucagon-like peptides: a double-edged therapeutic sword?
    TracyAnn Perry
    Section of Drug Design and Development, Laboratory of Neurosciences, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    Trends Pharmacol Sci 24:377-83. 2003
  6. ncbi request reprint A new Alzheimer's disease interventive strategy: GLP-1
    Tracy Ann Perry
    Drug Design and Development Section, Laboratory of Neurosciences, Gerontology Research Center, Intramural Research Program National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    Curr Drug Targets 5:565-71. 2004
  7. ncbi request reprint Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons
    Charles P Gilman
    Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    J Neurochem 87:1137-44. 2003
  8. pmc GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
    Yazhou Li
    Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, Baltimore, MD 21224, USA
    Proc Natl Acad Sci U S A 106:1285-90. 2009
  9. pmc GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease
    Yazhou Li
    Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, Baltimore, MD, USA
    J Alzheimers Dis 19:1205-19. 2010
  10. ncbi request reprint Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease
    TracyAnn Perry
    Drug Design and Development Section, Laboratory of Neurosciences, Gerontology Research Center, Intramural Research Program National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
    Curr Alzheimer Res 2:377-85. 2005

Detail Information

Publications16

  1. ncbi request reprint Behavioural, histological and immunocytochemical consequences following 192 IgG-saporin immunolesions of the basal forebrain cholinergic system
    T Perry
    Department of Psychology, Institute of Psychiatry, King s College London, London, United Kingdom
    Brain Res Bull 54:29-48. 2001
    ..It further highlights potential problems with this immunotoxin in long-term studies...
  2. ncbi request reprint A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells
    TracyAnn Perry
    Section of Drug, Design, and Development, Laboratory of Neuroscience, Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Pharmacol Exp Ther 300:958-66. 2002
    ..Due to its novel twin action, GLP-1 and exendin-4 have therapeutic potential for the treatment of diabetic peripheral neuropathy and these central nervous system disorders...
  3. ncbi request reprint Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4
    TracyAnn Perry
    Section of Drug Design and Development, Laboratory of Neuroscience, Gerontology Research Center, National Institute on Aging NIH, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    J Pharmacol Exp Ther 302:881-8. 2002
    ....
  4. ncbi request reprint Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron
    TracyAnn Perry
    Section of Drug Design and Development, Laboratory of Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA
    J Neurosci Res 72:603-12. 2003
    ..Collectively, these data suggest that GLP-1 can modify APP processing and protect against oxidative injury, two actions that suggest a novel therapeutic target for intervention in Alzheimer's disease...
  5. ncbi request reprint The glucagon-like peptides: a double-edged therapeutic sword?
    TracyAnn Perry
    Section of Drug Design and Development, Laboratory of Neurosciences, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    Trends Pharmacol Sci 24:377-83. 2003
  6. ncbi request reprint A new Alzheimer's disease interventive strategy: GLP-1
    Tracy Ann Perry
    Drug Design and Development Section, Laboratory of Neurosciences, Gerontology Research Center, Intramural Research Program National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    Curr Drug Targets 5:565-71. 2004
    ..This review will consider the potential therapeutic relevance of GLP-1 to CNS disorders, such as AD...
  7. ncbi request reprint Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons
    Charles P Gilman
    Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    J Neurochem 87:1137-44. 2003
    ..Collectively, our findings suggest that, by modulating calcium responses to glutamate and membrane depolarization, GLP-1 may play important roles in regulating neuronal plasticity and cell survival...
  8. pmc GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
    Yazhou Li
    Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, Baltimore, MD 21224, USA
    Proc Natl Acad Sci U S A 106:1285-90. 2009
    ..Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD...
  9. pmc GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease
    Yazhou Li
    Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, Baltimore, MD, USA
    J Alzheimers Dis 19:1205-19. 2010
    ..Together, these results suggest a potential value of Ex-4 in AD, particularly when associated with T2DM or glucose intolerance...
  10. ncbi request reprint Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease
    TracyAnn Perry
    Drug Design and Development Section, Laboratory of Neurosciences, Gerontology Research Center, Intramural Research Program National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
    Curr Alzheimer Res 2:377-85. 2005
    ..Furthermore, the ready availability of clinical material and the clinical history of its long term use in subjects with type 2 diabetes would support testing the value of GLP-1R agonists in AD trials...
  11. pmc Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy
    TracyAnn Perry
    Drug Design and Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Room 2C13, Gerontology Research Center, 5600 Nathan Shock Dr, Baltimore, MD 21224, USA
    Exp Neurol 203:293-301. 2007
    ..Our findings suggest a potential role for these peptides in the treatment of neuropathies, including that associated with type II diabetes mellitus...
  12. ncbi request reprint The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease
    TracyAnn Perry
    Laboratory of Neuroscience, Section of Drug Design and Development, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    J Alzheimers Dis 4:487-96. 2002
    ....
  13. ncbi request reprint New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists
    Nigel H Greig
    Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
    Ann N Y Acad Sci 1035:290-315. 2004
    ..Stimulation of the glucagon-like peptide-1 receptor (GLP-1R) in brain is associated with neurotrophic functions that, additionally, can protect cells against excess glutamate and other toxic insults...
  14. ncbi request reprint Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy
    Tracy Ann Perry
    Section of Drug Design and Development, Laboratory of Neurosciences, Gerontology Research Center, National Institute on Aging NIH, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
    Exp Neurol 190:133-44. 2004
    ..This combined stereological and electrophysiological method demonstrates a general approach that could be used for assessing the correlation between pathophysiological and functional parameters in animal models of toxic neuropathy...
  15. ncbi request reprint Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases
    Nigel H Greig
    Drug Design and Development Section, Lab of Neurosciences, Intramural Research Prog, National Inst on Aging, National Inst of Health, 5600 Nathan Shock Dr, Baltimore, MD 21224, USA
    Acta Neurobiol Exp (Wars) 64:1-9. 2004
    ....
  16. ncbi request reprint Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity
    Xiaoxiang Zhu
    Drug Design and Development Section, Laboratory of Neurosciences, Gerontology Research Center 4E02, Intramural Research Program, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Dr, Baltimore, Maryland 21224 6825, USA
    J Med Chem 46:5222-9. 2003
    ..In addition, an intact phthalimido moiety appeared to be requisite for TNF-alpha inhibitory activity...